Concepts (41)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eclampsia | 1 | 2017 | 5 | 0.580 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 12 | 0.580 |
Why?
|
| Puerperal Disorders | 1 | 2017 | 14 | 0.570 |
Why?
|
| ADAMTS13 Protein | 1 | 2017 | 126 | 0.550 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 54 | 0.540 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 216 | 0.460 |
Why?
|
| Androgens | 1 | 2025 | 47 | 0.230 |
Why?
|
| Medicare Part D | 1 | 2024 | 5 | 0.230 |
Why?
|
| Prescription Drugs | 1 | 2024 | 15 | 0.230 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 12 | 0.190 |
Why?
|
| Lymphoma | 1 | 2021 | 22 | 0.190 |
Why?
|
| Prostatic Neoplasms | 1 | 2025 | 271 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 15 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 660 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 13 | 0.150 |
Why?
|
| Female | 4 | 2018 | 14661 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2017 | 67 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.140 |
Why?
|
| Plasma Exchange | 1 | 2017 | 103 | 0.140 |
Why?
|
| Humans | 6 | 2025 | 27165 | 0.130 |
Why?
|
| Male | 4 | 2025 | 13041 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 318 | 0.130 |
Why?
|
| Neoplasms | 1 | 2024 | 768 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 384 | 0.120 |
Why?
|
| Adult | 2 | 2017 | 7506 | 0.120 |
Why?
|
| Prognosis | 1 | 2017 | 763 | 0.120 |
Why?
|
| Oklahoma | 1 | 2017 | 979 | 0.110 |
Why?
|
| Pregnancy | 1 | 2017 | 1154 | 0.110 |
Why?
|
| Aged | 2 | 2025 | 5229 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2017 | 2285 | 0.090 |
Why?
|
| Middle Aged | 2 | 2025 | 6912 | 0.090 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 10 | 0.060 |
Why?
|
| Cost Savings | 1 | 2024 | 19 | 0.060 |
Why?
|
| Genomics | 1 | 2025 | 116 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 377 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 446 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 76 | 0.050 |
Why?
|
| Mutation | 1 | 2025 | 819 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 279 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 312 | 0.040 |
Why?
|
| Animals | 1 | 2018 | 10093 | 0.010 |
Why?
|